Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175)

Matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • AstraZeneca (gefitinib) • Roche Products (erlotinib) Patient/carer groups • Afiya Trust • Black Health Agency • British Lung Foundation • Cancer Black Care • Cancer Equality • Equalities National Council • Helen Rollason Heal Cancer Charity • Independent Age • Independent Cancer Patients' Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Great Britain • Muslim Health Network • Roy Castle Lung Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus • United Kingdom Lung Cancer Coalition Professional groups • Association of Cancer Physicians • Association of Respiratory Nurse Specialists • British Association for Services to the Elderly	General • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Health Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium Comparator manufacturers • Accord Healthcare Ltd (docetaxel) • Actavis UK (docetaxel) • Hospira UK (docetaxel) • Medac UK (docetaxel) • Sandoz (docetaxel) • Sanofi (docetaxel) • Teva UK (docetaxel) Relevant research groups • British Thoracic Oncology Group

Consultees	**Commentators (no right to submit or appeal)**
• British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Thoracic Society (Lung Cancer and Mesothelioma Working party) • Cancer Networks Pharmacists Forum • Cancer Research UK • National Lung Cancer Forum for Nurses • Primary Care Respiratory Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <u>Others</u> • Department of Health • North Central London PCT Cluster • Nottinghamshire PCT Cluster • Welsh Government	• Cochrane Lung Cancer Group • Health Research Authority • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Research Institute for the Care of Older People <u>Assessment Group</u> • Liverpool Reviews and Implementation Group (LRIG) • National Institute for Health Research Health Technology Assessment Programme <u>Associated Guideline Groups</u> • National Collaborating Centre for Cancer <u>Associated Public Health Groups</u> • None

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.